|
Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 26, No 15S (May 20 Supplement), 2008: 15096
© 2008 American Society of Clinical Oncology
Clinical impact on time to progression (TTP) of acneiform skin lesions in cetuximab-based regimens in colorectal cancer
J. Bosch,
L. Abella,
A. Viudez,
A. Chopitea,
J. Rodriguez,
J. Rodriguez,
J. Aristu,
L. Arbea,
L. Arbea,
C. Reyna and
J. García-Foncillas
University of Navarra Clinic, Pamplona, Spain
15096
Background: Cetuximab, a chimeric IgG1 (immunoglobulin G1) monoclonal antibody that binds to the extracellular domain of EGFR, inhibits its activation and modulate tumor-cell growth. The presence of acneiform rash has been associated with improved survival in some studies. Methods: A retrospective review of 62 patients with metastatic colorectal cancer treated with cetuximab-based regimens in our center from July 2004 to August 2007 has been performed. Results: Oxaliplatin and irinotecan- based regimens were included. Overall median time to progression was 6.6 months (CI 95%: 5.4–7.9). No significant differences were observed in time to progression (TTP) between the regimens considered. Rash grade was: 0 (n=17), 1 (n=16), 2 (n=20) and 3 (n=5). Statistical differences were found in TTP when patients that did not develop rash (4.88, CI 95%: 2.7–7.0) were compared to patients with any grade of rash (7.38, CI: 5.9–8.8) (p<0,05). Comparisons among subgroups of rash did not show statistical differences. No differences were observed between rash grade 1 and 2 or more subgroups. Conclusions: The presence of rash whatever its grade is associated with a significant improvement on time to progression in cetuximab-based regimens in metastatic colorectal cancer.
No significant financial relationships to disclose.
|
